Foundation Medicine announced on Thursday that UnitedHealthcare will provide commercial coverage for the firm’s FoundationOne CDx and FoundationOne Liquid CDx companion diagnostic (CDx) tests.
FoundationOne CDx is a tissue-based comprehensive genomic profiling (CGP) test for solid tumors in patients with unresectable and metastatic cancer who are being considered for treatment with immune checkpoint inhibitors. FoundationOne Liquid CDx is a CGP liquid biopsy test for patients with advanced breast cancer, metastatic non-small cell lung cancer (NSCLC), recurrent ovarian cancer, and metastatic castrate-resistant prostate cancer. Both can be used to identify patients who may benefit for treatment from specific targeted therapies.
“We believe patients and their physicians deserve the highest quality genomic testing to make informed decisions about personalized treatment,” Foundation Medicine CEO Dr. Brian Alexander said in a statement. “UnitedHealthcare’s coverage decision will improve patient access to molecular profiling and enable better outcomes for patients.”
UnitedHealthcare’s coverage for the tests will be effective April 1, 2023. FoundationOne CDx and FoundationOne Liquid CDx are also covered by other commercial providers, as well as Medicare and Medicare Advantage.
